X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (16) 16
index medicus (15) 15
neurosciences (12) 12
life sciences (11) 11
analysis (10) 10
disease models, animal (10) 10
clinical neurology (9) 9
macaca fascicularis (8) 8
parkinsons-disease (8) 8
[ sdv ] life sciences [q-bio] (7) 7
female (7) 7
levodopa-induced dyskinesia (7) 7
primates (7) 7
analysis of variance (6) 6
basal ganglia (6) 6
dopa (6) 6
dyskinesia, drug-induced - drug therapy (6) 6
male (6) 6
mptp (6) 6
mptp poisoning - drug therapy (6) 6
parkinson's disease (6) 6
rats (6) 6
cognition disorders - physiopathology (5) 5
dopa-induced dyskinesia (5) 5
dose-response relationship, drug (5) 5
dyskinesia (4) 4
levodopa - adverse effects (4) 4
models (4) 4
neurobiology (4) 4
rat (4) 4
time factors (4) 4
animal behavior (3) 3
antiparkinson agents - adverse effects (3) 3
cognition (3) 3
disease (3) 3
drug therapy, combination (3) 3
glutamate (3) 3
l-dopa (3) 3
medical and health sciences (3) 3
medicin och hälsovetenskap (3) 3
methyl aspartate (3) 3
mice (3) 3
monkey (3) 3
motor activity - drug effects (3) 3
movement disorders (3) 3
neurons and cognition (3) 3
non-human primate (3) 3
treatment outcome (3) 3
a receptor antagonist (2) 2
acetylcholinesterase (2) 2
adeno-associated viral vector (2) 2
adenosine a2 receptor antagonists - administration & dosage (2) 2
aging (2) 2
alzheimer disease - physiopathology (2) 2
alzheimer's disease (2) 2
amantadine - therapeutic use (2) 2
animal-models (2) 2
aspartate (2) 2
basic medicine (2) 2
behavior, animal - drug effects (2) 2
behavior, animal - physiology (2) 2
behavioral sciences (2) 2
brain (2) 2
brain - physiopathology (2) 2
cantab (2) 2
cognition disorders - drug therapy (2) 2
cognition disorders - genetics (2) 2
cognition disorders - psychology (2) 2
conditioning, operant - drug effects (2) 2
corpus striatum - metabolism (2) 2
dopamine (2) 2
dopamine agents - adverse effects (2) 2
dopaminergic-neurons (2) 2
drug evaluation, preclinical - methods (2) 2
dyskinesia, drug-induced - etiology (2) 2
dyskinesia, drug-induced - physiopathology (2) 2
dyskinesia, drug-induced - psychology (2) 2
excitatory amino acid antagonists - therapeutic use (2) 2
expression (2) 2
gene therapy (2) 2
health aspects (2) 2
humans (2) 2
hypokinesia - drug therapy (2) 2
hypokinesia - physiopathology (2) 2
hypokinesia - psychology (2) 2
imidazoles - therapeutic use (2) 2
levodopa (2) 2
levodopa - administration & dosage (2) 2
levodopa - toxicity (2) 2
macaca (2) 2
macaca mulatta (2) 2
macaque (2) 2
medicinska och farmaceutiska grundvetenskaper (2) 2
metabotropic glutamate receptors (2) 2
mice, inbred c57bl (2) 2
monkeys (2) 2
motor skills disorders - drug therapy (2) 2
motor skills disorders - physiopathology (2) 2
motor skills disorders - psychology (2) 2
mouse (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Movement Disorders, ISSN 0885-3185, 07/2013, Volume 28, Issue 8, pp. 1088 - 1096
Journal Article
Journal Article
Neurobiology of Learning and Memory, ISSN 1074-7427, 10/2015, Volume 124, pp. 123 - 129
Journal Article
Journal Article
Movement Disorders, ISSN 0885-3185, 10/2018, Volume 33, Issue 10, pp. 1555 - 1557
Journal Article
Journal Article
Movement Disorders, ISSN 0885-3185, 10/2018, Volume 33, Issue 10, pp. 1555 - 1557
Relevant conflicts of interest/financial disclosures: Nothing to report. 
TRIAL | MOTOR FLUCTUATIONS | LEVODOPA-INDUCED DYSKINESIA | RAT | ALLOSTERIC MODULATOR DIPRAGLURANT | MODEL | CLINICAL NEUROLOGY | PARKINSONS-DISEASE | Analysis | Financial disclosure
Journal Article
Movement Disorders, ISSN 0885-3185, 10/2018, Volume 33, Issue 10, pp. 1619 - 1631
Journal Article
Neuropharmacology, ISSN 0028-3908, 11/2016, Volume 110, Issue Pt A, pp. 48 - 58
Istradefylline (KW-6002), an adenosine A2A receptor antagonist, is used adjunct with optimal doses of L-3,4-dihydroxyphenylalanine ( -DOPA) to extend on-time... 
KW-6002 | Istradefylline | Cognition | Parkinson's disease | MPTP | l-DOPA-induced dyskinesia | L-DOPA-induced dyskinesia | ASYMPTOMATIC MONKEYS | ADENOSINE A(2A) | DISEASE PATIENTS | DOPA-INDUCED DYSKINESIA | BASAL GANGLIA | L-3,4-DIHYDROXYPHENYLALANINE-INDUCED DYSKINESIA | NEUROSCIENCES | PREFRONTAL CORTEX | LEVODOPA-INDUCED DYSKINESIA | MPTP-TREATED MONKEYS | A(2A) RECEPTOR ANTAGONIST | PHARMACOLOGY & PHARMACY | Dyskinesia, Drug-Induced - physiopathology | Dyskinesia, Drug-Induced - psychology | MPTP Poisoning - physiopathology | Macaca fascicularis | Motor Skills Disorders - psychology | Purines - administration & dosage | Dose-Response Relationship, Drug | Adenosine A2 Receptor Antagonists - administration & dosage | Levodopa - administration & dosage | Dyskinesia, Drug-Induced - drug therapy | Hypokinesia - physiopathology | Female | Motor Skills Disorders - drug therapy | Hypokinesia - psychology | Drug Therapy, Combination | Cognition Disorders - psychology | Hypokinesia - drug therapy | Drug Evaluation, Preclinical - methods | Cognition Disorders - physiopathology | MPTP Poisoning - psychology | Treatment Outcome | Levodopa - toxicity | Cognition Disorders - drug therapy | MPTP Poisoning - drug therapy | Animals | Motor Skills Disorders - physiopathology | Dopa | Drug therapy | Health aspects | Analysis | Movement disorders
Journal Article
Brain, ISSN 0006-8950, 08/2019, Volume 142, Issue 8, pp. 2402 - 2416
Abstract Ever since its introduction 40 years ago l-3,4-dihydroxyphenylalanine (l-DOPA) therapy has retained its role as the leading standard medication for... 
l-DOPA | gene therapy | non-human primate | MPTP | Original | adeno-associated viral vector
Journal Article
Neuropharmacology, ISSN 0028-3908, 07/2016
Istradefylline (KW-6002), an adenosine A2A receptor antagonist, is used adjunct with optimal doses of L-3,4-dihydroxyphenylalanine (l-DOPA) to extend on-time... 
Life Sciences | Environmental Sciences
Journal Article